Lmr Partners Reduces $2M in ABIVAX Société Anonyme ($ABVX)

Lmr Partners has reduced its stake in ABIVAX Socie9te9 Anonyme (NasdaqGM: ABVX) by 19%, according to its latest 13F filing with the SEC. The fund cut its holdings by 18,000 shares, leaving it with 76,552 shares valued at approximately $10.17 million as of the reporting period.

What Changed in Lmr Partners' ABIVAX Position

Lmr Partners trimmed its position in ABIVAX by 18,000 shares, resulting in a 19% decrease. The fund now holds 76,552 shares, down from 94,552 shares previously, with the current holdings valued at about $10.17 million.

Other Institutional Activity in ABIVAX

TCG Crossover Management, LLC reduced its position in ABIVAX by 630,511 shares, ending with 6,481,085 shares worth roughly $721.67 million, an 8.9% decrease. UBS Group AG increased its stake by 123,500 shares, bringing its total to 4,547,406 shares valued at $506.35 million, a 2.8% increase. Darwin Global Management, Ltd. added 290,156 shares, growing its holdings by 9.1% to 3,468,657 shares, valued at $352.07 million. Morgan Stanley significantly reduced its position by 1,447,036 shares, a 45.9% decrease, leaving it with 1,704,958 shares worth $189.85 million. Vestal Point Capital, LP trimmed its holdings by 400,000 shares, a 21.1% decrease, resulting in 1,500,000 shares valued at $167.03 million.

ABIVAX Société Anonyme Stock Up 17.2%

Shares of ABIVAX Socie9te9 Anonyme traded near $132.83 on Wednesday. The company has a market cap of $10.63 billion and a forward P/E ratio of -40.75, as it is not currently profitable. It has a beta of -0.2, indicating it is less volatile than the market. The stock's 52-week range is between $7.41 and $148.83. It has a 50-day moving average of $111.05 and a 200-day moving average of $111.25. ABIVAX maintains a strong liquidity position with a current ratio of 8.25 and a quick ratio of 8.07, though it has a debt-to-equity ratio of 7.96.

Recent Earnings

ABIVAX reported revenue of $4.92 million, with a revenue growth rate of 35.2%. The company is not currently profitable, with a negative return on equity of -157.07%. The next earnings report is expected on September 21, 2026.

Insider Buying and Selling at ABIVAX Société Anonyme

Sofinnova Crossover sold 1,000,000 shares on January 8, 2026, at an average price of $133.70. Previously, on October 28, 2025, Sofinnova Crossover SLP and Sofinnova Crossover sold 1,200,000 shares each at $92.75 per share.

Analysts Set New Price Targets

On June 30, 2026, Jefferies upgraded ABIVAX to a 'buy' rating with a price target of $158. Leerink Partners and BTIG maintained their 'buy' ratings with targets of $148 and $175, respectively. Earlier in June, Jefferies downgraded the stock to 'hold' with a $90 target, while Truist Securities and Morgan Stanley maintained 'buy' ratings with targets of $135 and $132. The consensus recommendation is 'buy', with an average price target of $150.73 from 11 analysts.

About ABIVAX Socie9te9 Anonyme

ABIVAX Socie9te9 Anonyme is a biotechnology company based in Paris, France, specializing in developing therapies for chronic inflammatory diseases. Its lead product, obefazimod, is in Phase 3 trials for ulcerative colitis and Phase 2b trials for Crohn's disease. The company, led by CEO Marc M. P. de Garidel, was founded in 2013 and employs 80 people.

Bottom Line

Lmr Partners' decision to reduce its stake in ABIVAX by 19% reflects its current investment strategy. Investors keep an eye on such filings to gauge institutional sentiment, though it's important to remember these reports are backward-looking. ABIVAX continues to be a subject of interest in the biotechnology sector, with analysts maintaining a generally positive outlook.